Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

OnlineFirst

January 05, 2021

  • Subject Review | AUTHOR MANUSCRIPT
    Role of polo-like kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for cancer management
    Debra R. Garvey, Gagan Chhabra, Mary A. Ndiaye and Nihal Ahmad
    Mol Cancer Ther January 5 2021 DOI:10.1158/1535-7163.MCT-20-0741

  • Subject Review | AuthorChoice | AUTHOR MANUSCRIPT
    Salting the soil: Targeting the microenvironment of brain metastases
    Ethan S. Srinivasan, Aaron C Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M Ashley, Peter E. Fecci and Mustafa Khasraw
    Mol Cancer Ther January 5 2021 DOI:10.1158/1535-7163.MCT-20-0579

December 23, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Improved anti-Tumor Activity of the Fluoropyrimidine Polymer CF10 in pre-Clinical Colorectal Cancer Models thru Distinct Mechanistic and Pharmacological Properties
    William H. Gmeiner, Anthony Dominijanni, Alex O Haber, Lais P Ghiraldeli, David L. Caudell, Ralph D`Agostino, Boris C Pasche, Thomas L Smith, Zhiyong Deng, Sezgin Kiren, Chinnadurai Mani, Komaraiah Palle and Jonathan R. Brody
    Mol Cancer Ther December 23 2020 DOI:10.1158/1535-7163.MCT-20-0516

  • Research Article | AUTHOR MANUSCRIPT
    The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.
    Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R Hodges, Courtney W Hudgens, Grant M. Fischer, Catherine K Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. MacKinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng and Y.N. Vashisht Gopal
    Mol Cancer Ther December 23 2020 DOI:10.1158/1535-7163.MCT-20-0430

December 22, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of Small Molecule-Drug Conjugates targeting Carbonic Anhydrase IX
    Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri and Samuele Cazzamalli
    Mol Cancer Ther December 22 2020 DOI:10.1158/1535-7163.MCT-20-0361

  • Research Article | AUTHOR MANUSCRIPT
    Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12
    Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zi, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D Economides, Douglas E. Williams and Sriram Sathyanarayanan
    Mol Cancer Ther December 22 2020 DOI:10.1158/1535-7163.MCT-20-0484

December 15, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
    Marika K. A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa and Klaus Elenius
    Mol Cancer Ther December 15 2020 DOI:10.1158/1535-7163.MCT-20-0590

  • Research Article | AUTHOR MANUSCRIPT
    Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis
    Xuemei Xie, Jangsoon Lee, Huey Liu, Troy Pearson, Alexander Y Lu, Debu Tripathy, Gayathri R. Devi, Chandra Bartholomeusz and Naoto T. Ueno
    Mol Cancer Ther December 15 2020 DOI:10.1158/1535-7163.MCT-19-1160

  • Research Article | AUTHOR MANUSCRIPT
    Neutralization of TGF-β improves tumor immunity and reduces tumor progression in ovarian carcinoma
    Brandon M Roane, Selene Meza-Perez, Ashwini A. Katre, Whitney N. Goldsberry, Troy D Randall, Lyse A Norian, Michael J. Birrer and Rebecca C. Arend
    Mol Cancer Ther December 15 2020 DOI:10.1158/1535-7163.MCT-20-0412

December 11, 2020

  • Small Molecule Therapeutics | AuthorChoice
    SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
    Maysoun Shomali, Jane Cheng, Fangxian Sun, Malvika Koundinya, Zhuyan Guo, Andrew T. Hebert, Jessica McManus, Mikhail N. Levit, Dietmar Hoffmann, Albane Courjaud, Rosalia Arrebola, Hui Cao, Jack Pollard, Joon Sang Lee, Laurent Besret, Anne Caron, Dinesh S. Bangari, Pierre-Yves Abecassis, Laurent Schio, Youssef El-Ahmad, Frank Halley, Michel Tabart, Victor Certal, Fabienne Thompson, Gary McCort, Bruno Filoche-Rommé, Hong Cheng, Carlos Garcia-Echeverria, Laurent Debussche and Monsif Bouaboula
    Mol Cancer Ther December 11 2020 DOI:10.1158/1535-7163.MCT-20-0390

December 09, 2020

  • Research Article | AUTHOR MANUSCRIPT
    HDP-101, anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells
    Vianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, Anja Baumann, Nicola Giesen, Anikó Pálfi, Christoph Müller, Christian Lutz, Torsten Hechler, Michael Kulke, Carsten Müller-Tidow, Alwin Krämer, Hartmut Goldschmidt, Andreas Pahl and Marc S. Raab
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0287

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A report by the Pediatric Preclinical Testing Consortium
    Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan D. Gill, Douglas J Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb and Richard Gorlick
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0406

  • Research Article | AUTHOR MANUSCRIPT
    Predicting tumor killing and T-cell activation by T-Cell Bispecific antibodies as a function of target expression: combining in vitro experiments with systems modeling
    Arthur J Van De Vyver, Tina Weinzierl, Miro J Eigenmann, Nicolas Frances, Sylvia Herter, Regula B Buser, Jitka Somandin, Sarah Diggelmann, Florian Limani, Thorsten Lehr, Marina Bacac and Antje-Christine Walz
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0269

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Inhibition of intermedin (adrenomedullin 2) suppresses the growth of glioblastoma and increases the antitumor activity of temozolomide
    Luping Huang, Denian Wang, Zhongxue Feng, Huan Zhao, Fei Xiao, Yong'gang Wei, Heng Zhang, Hongyu Li, Lingmiao Kong, Min Li, Fei Liu, Haili Zhang and Wei Zhang
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0619

  • Research Article | AUTHOR MANUSCRIPT
    Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
    Aaron Balog, Tai-an Lin, Derrick Maley, Johnni Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng and John T Hunt
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0251

  • Research Article | AUTHOR MANUSCRIPT
    Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro
    Sarah E Kohrt, Wisam N Awadallah, Robert A Phillips, Thomas C. Case, Renjie Jin, Jagpreet S Nanda, Xiuping Yu, Peter E Clark, Yajun Yi, Robert J Matusik, Philip D Anderson and Magdalena M Grabowska
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0244

  • Research Article | AUTHOR MANUSCRIPT
    Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
    Amy Kwan, Natalie J Winder, Emer Atkinson, Haider H Al-Janabi, Richard J Allen, Russell Hughes, Mohammed Ridha Moamin, Rikah Louie, Dhananjay Evans, Matthew Hutchinson, Drew T Capper, Katie Cox, Joshua T Handley, Adam Wilshaw, Taewoo Kim, Simon J Tazzyman, Sanjay K Srivastava, Penelope D Ottewell, Jayakumar Vadakekolathu, Alan Graham Pockley, Claire E Lewis, Janet E Brown, Sarah Danson, Joe Conner and Munitta Muthana
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0748

  • Research Article | AUTHOR MANUSCRIPT
    EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1
    Brenna Weadick, Debasis Nayak, Avinash K Persaud, Sau Wai Hung, Radhika Raj, Moray J Campbell, Wei Chen, Junan Li, Terence M. Williams and Rajgopal Govindarajan
    Mol Cancer Ther December 9 2020 DOI:10.1158/1535-7163.MCT-20-0316

December 08, 2020

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Single-dose anti-PD-L1/IL-15 fusion protein KD033 generates synergistic anti-tumor immunity with robust tumor-immune gene signatures and memory responses
    Stella A Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Zhikai Zhang, Sam Feldstein, Radovan Lumban-Tobing, Danielle K Almstead, Faical Miyara and Jeegar Patel
    Mol Cancer Ther December 8 2020 DOI:10.1158/1535-7163.MCT-20-0457

  • Research Article | AUTHOR MANUSCRIPT
    Leflunomide suppresses the growth of LKB1-inactivated tumors in the immunocompetent host and attenuates distant cancer metastasis
    Rui Jin, Boxuan Liu, Xiuju Liu, Yijian Fan, Wei Peng, Chunzi Huang, Adam I. Marcus, Gabriel L. Sica, Melissa Gilbert-Ross, Yuan Liu and Wei Zhou
    Mol Cancer Ther December 8 2020 DOI:10.1158/1535-7163.MCT-20-0567

December 07, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Novel Auristatins with High Bystander and Cytotoxic Activities in Drug-Efflux Positive Tumor Models
    Philip N. Moquist, Tim D. Bovee, Andrew B Waight, Jamie A. Mitchell, Jamie B. Miyamoto, Marsha L. Mason, Kim K Emmerton, Nicole Stevens, Cindy Balasubramanian, Jessica K. Simmons, Robert P. Lyon, Peter D. Senter and Svetlana O. Doronina
    Mol Cancer Ther December 7 2020 DOI:10.1158/1535-7163.MCT-20-0618

December 04, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Cabozantinib unlocks efficient in vivo targeted delivery of neutrophil-loaded nanoparticles into murine prostate tumors
    Kiranj Kishor Chaudagar, Natalie Landon-Brace, Aniruddh Solanki, Hanna M Hieromnimon, Emma Hegermiller, Wen Li, Yue Shao, John Joseph, Devan J. Wilkins, Kaela M Bynoe, Xiang-Ling Li, John G. Clohessy, Soumya Ullas, Jeffrey M. Karp and Akash Patnaik
    Mol Cancer Ther December 4 2020 DOI:10.1158/1535-7163.MCT-20-0167

  • Research Article | AUTHOR MANUSCRIPT
    THE HISTONE METHYLTRANSFERASE GENE G9A IS REGULATED BY NUCLEAR RECEPTOR 4A1 (NR4A1) IN ALVEOLAR RHABDOMYOSARCOMA CELLS
    Rupesh Shrestha, Kumaravel Mohankumar, Un-Ho Jin, Gregory G Martin and Stephen Safe
    Mol Cancer Ther December 4 2020 DOI:10.1158/1535-7163.MCT-20-0474

  • Research Article | AUTHOR MANUSCRIPT
    Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC resistant to Second-Line Antiandrogen Therapy
    Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E Sabaawy, Wun-Jae Kim, Roy J Vaz, Gabriele Cruciani and Isaac Yi Kim
    Mol Cancer Ther December 4 2020 DOI:10.1158/1535-7163.MCT-20-0417

  • Research Article | AUTHOR MANUSCRIPT
    A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers
    Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiuxia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J Freemantle, Jonathan M. Kurie, Xi Liu and Ethan Dmitrovsky
    Mol Cancer Ther December 4 2020 DOI:10.1158/1535-7163.MCT-19-0987

December 03, 2020

  • Research Article | AUTHOR MANUSCRIPT
    An anti-CD22-seco-CBI-Dimer ADC for the treatment of non-Hodgkin lymphoma that provides a longer duration of response than auristatin ADCs in preclinical models
    Shang-Fan Yu, Donna W Lee, Bing Zheng, Geoffrey del Rosario, Douglas Leipold, Helen Booler, Fiona Zhong, Montserrat Carrasco-Triguero, Kyu Hong, Peter Yan, Rebecca K Rowntree, Melissa M. Schutten, Thomas Pillow, Jack D Sadowsky, Peter S. Dragovich and Andrew G Polson
    Mol Cancer Ther December 3 2020 DOI:10.1158/1535-7163.MCT-20-0046

  • Research Article | AUTHOR MANUSCRIPT
    The HPV and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils
    Muriel Charlotte Bernhard, Anabel Zwick, Tobias Mohr, Gilles Gasparoni, Oybek Khalmurzaev, Vladimir Borisovich Matveev, Philine Loertzer, Alexey Pryalukhin, Arndt Hartmann, Carol-Immanuel Geppert, Hagen Loertzer, Heiko Wunderlich, Carsten Maik Naumann, Holger Kalthoff, Kerstin Junker, Sigrun Smola and Stefan Lohse
    Mol Cancer Ther December 3 2020 DOI:10.1158/1535-7163.MCT-20-0173

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    AZD0364 is a potent and selective ERK1/2 inhibitor which enhances anti-tumour activity in KRAS mutant tumour models when combined with the MEK inhibitor selumetinib
    Vikki Flemington, Emma J Davies, David Robinson, Linda C Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E Willis, Martine P Roudier, Claire Rooney, Elizabeth A Coker, Patricia Jaaks, Mathew J Garnett, Stephen E Fawell, Clifford D Jones, Richard A Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease and Paul D Smith
    Mol Cancer Ther December 3 2020 DOI:10.1158/1535-7163.MCT-20-0002

  • Research Article | AUTHOR MANUSCRIPT
    Development of Novel Antibody-Camptothecin Conjugates
    Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W Meyer, Julia H Cochran, Nicole M. Okeley, Kim K Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C Zaval, Katie M Snead, Steven Jin, Lauren M Farr, Maureen C Ryan, Peter D. Senter and Scott C. Jeffrey
    Mol Cancer Ther December 3 2020 DOI:10.1158/1535-7163.MCT-20-0526

December 02, 2020

  • Research Article | AUTHOR MANUSCRIPT
    Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer
    Leslie A Parsels, Carl G Engelke, Joshua Parsels, Sheryl A Flanagan, Qiang Zhang, Daria Tanska, Daniel R Wahl, Christine E Canman, Theodore S. Lawrence and Meredith A. Morgan
    Mol Cancer Ther December 2 2020 DOI:10.1158/1535-7163.MCT-20-0365

  • Research Article | AUTHOR MANUSCRIPT
    A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
    Kim A Reiss, Max M Wattenberg, Nevena Damjanov, Elizabeth Prechtel Dunphy, Mona Jacobs-Small, M. Judy Lubas, James Robinson, Lisa Dicicco, Luis Garcia-Marcano, Michael A Giannone, Thomas B Karasic, Emma E Furth, Erica L Carpenter, Andrzej P Wojcieszynski, Robert H. Vonderheide, Gregory L. Beatty and Edgar Ben-Josef
    Mol Cancer Ther December 2 2020 DOI:10.1158/1535-7163.MCT-20-0632

November 17, 2020

  • Subject Review | AUTHOR MANUSCRIPT
    Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides
    Jamie V Shiah, Jennifer R. Grandis and Daniel E Johnson
    Mol Cancer Ther November 17 2020 DOI:10.1158/1535-7163.MCT-20-0599

November 06, 2020

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Rigosertib induces mitotic arrest and apoptosis in RAS-driven rhabdomyosarcoma and neuroblastoma
    Joshua T. Kowalczyk, Xiaolin Wan, Edjay R. Hernandez, Ruibai Luo, Gaelyn C. Lyons, Kelli M Wilson, Devorah C. Gallardo, Kristine A. Isanogle, Christina M Robinson, Arnulfo Mendoza, Christine M Heske, Jinqiu-Qiu Chen, Xiaoling Luo, Alexander E. Kelly, Simone Difilippantonio, Robert W. Robey, Craig J. Thomas, Dan L. Sackett, Deborah K. Morrison, Paul A. Randazzo, Lisa M Miller Jenkins and Marielle E. Yohe
    Mol Cancer Ther November 6 2020 DOI:10.1158/1535-7163.MCT-20-0525

  • Subject Review | AUTHOR MANUSCRIPT
    Therapeutic vulnerabilities of transcription factors in AML
    Irum Khan, Elizabeth A. Eklund and Andrei L Gartel
    Mol Cancer Ther November 6 2020 DOI:10.1158/1535-7163.MCT-20-0115

  • Research Article | AUTHOR MANUSCRIPT
    BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma
    Sara Busacca, Laura O'Regan, Anita Singh, Annabel J Sharkey, Alan G Dawson, Joanna Dzialo, Aimee Parsons, Neelam Kumar, Laurel M Schunselaar, Naomi Guppy, Apostolos Nakas, Michael Sheaff, Aaron S Mansfield, Sam M. Janes, Paul Baas, Andrew M Fry and Dean A Fennell
    Mol Cancer Ther November 6 2020 DOI:10.1158/1535-7163.MCT-20-0363

View by section

OnlineFirst articles are published online before they appear in a regular issue of the journal. Molecular Cancer Therapeutics publishes two types of OnlineFirst articles.

OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.

Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.

Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.

When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).

While an article is OnlineFirst, it may be cited as shown in the following example:

Amin DN, Ahuja A, Yaswen, et al. A TORC2-Akt Feedforward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. (October 5, 2015) Mol Cancer Ther, 10.1158/1535-7163.MCT-15-0403.

Sign up to be notified each time OnlineFirst articles are posted in Molecular Cancer Therapeutics.

  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement